Remote Patient Monitoring Devices Market Size, Share, Trends, Growth and Forecast 2026–2034

Remote Patient Monitoring Devices Market Overview Analysis By Fortune Business Insights

Market Summary

According to Fortune Business Insights: The global remote patient monitoring (RPM) devices market was valued at USD 59.92 billion in 2025 and is projected to grow from USD 71.29 billion in 2026 to USD 289.77 billion by 2034, exhibiting a CAGR of 19.16% during the forecast period. Remote patient monitoring is the use of digital technologies by healthcare professionals to electronically capture and monitor patient health data for quality care and consultation. The market spans multi-parameter monitoring, respiratory monitoring, blood glucose monitoring, and cardiac monitoring devices and services, deployed across hospital, home, and remote care settings. North America dominated the market with a 48.06% share in 2025, valued at USD 28.8 billion.

Get a Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/106328

Key Market Drivers

Growing disease burden among the geriatric population is the primary market driver. The WHO projects that the number of elderly people aged 65 and older will reach 1.5 billion by 2050. This expanding population carries a disproportionately high burden of chronic conditions including cardiovascular disease, diabetes, arthritis, hypertension, cancer, and stroke — all requiring continuous vital-sign monitoring and effective disease management. The majority (70%) of home healthcare patients are 65 years of age and above, making the elderly segment the largest and most consistent consumer of RPM devices and services.

The COVID-19 pandemic provided transformative structural momentum for the market. According to the American Medical Association, approximately nine out of ten healthcare providers stated they had invested or were investing in remote monitoring technologies in 2020. In April 2020, the U.S. FDA permitted Dexcom and Abbott to provide continuous glucose monitoring systems in hospitals to minimize patient contact — a regulatory accommodation that normalized remote monitoring as a clinical standard. Philips' connected care business registered USD 6,834.0 million in 2020 revenue, an increase of 19% over 2019, reflecting pandemic-driven adoption at scale. Telehealth utilization has increased 38 times compared to pre-pandemic years according to McKinsey, with RPM serving as a cornerstone of this transformation.

Market Trends

Integration of IoT, AI, and machine learning into RPM systems is the defining market trend. AI improves monitoring accuracy by analyzing large volumes of patient data to identify patterns not immediately apparent to clinicians. A medical-grade rechargeable sensor manufactured by BioIntelliSense measures more than 20 vital signs, recording 1,440 measurements per day — illustrating the data intensity of next-generation wearables. Bluetooth-connected sensors, cloud-based platforms, and actuator networks are enabling seamless, real-time data transfer from patients to healthcare providers, driving demand for both hardware devices and monitoring service subscriptions. In May 2020, Philips launched its next-generation wireless wearable biosensor BX100 for clinical supervision of COVID-19 patients, demonstrating the pace of product innovation accelerating across the market.

Market Restraints

Lack of remote monitoring solution deployment in low- and middle-income countries is the primary restraint on market growth. The high implementation cost of RPM systems — ranging from USD 275 to USD 7,963 per patient annually according to the Journal of Telemedicine and Telecare — deters adoption in resource-constrained environments. Deployment requires sufficient investments in hardware, IT personnel, and connectivity infrastructure. While countries such as the U.S. have implemented favorable reimbursement policy changes — including the January 2021 Centers for Medicare and Medicaid Services amendments to the Physician Fee Schedule providing RPM reimbursement — many developing nations lack equivalent regulatory or reimbursement support, compounding awareness and access barriers.

Segmentation Analysis

By type, the services segment is projected to account for the dominant 64.18% market share in 2026, driven by surging demand for remote monitoring services for blood glucose monitoring, cardiac monitoring, and vital signs — accelerated during the pandemic and sustained by technology-driven service subscriptions. In October 2021, OnSkyHealth International launched SkyPad, a virtual care solution for contact-free vital signs monitoring. The products/devices segment is growing significantly, supported by company investment in patient-centric chronic disease management solutions. In August 2023, CardiAI Inc. launched the BPAro, a 24-hour ambulatory blood pressure monitoring system, illustrating continued hardware innovation.

By application, the cardiovascular diseases segment is projected to hold a 47.27% share in 2026, reflecting the high prevalence of coronary artery disease — affecting more than 18.2 million U.S. adults aged 20 and above according to the CDC — alongside rising clinical deployment of blood pressure monitors and vital signs monitors. The diabetes segment is expected to grow at a faster CAGR, driven by the widespread adoption of blood glucose monitoring devices for daily glucose tracking. In August 2021, SmartMeter launched an iGlucose monitor targeting gestational diabetes — a condition affecting approximately 700,000 U.S. pregnancies annually. The oncology and others segments contribute incremental growth.

By end user, the providers segment is projected to lead with a 47.38% share in 2026, driven by growing patient visits, rising chronic disease prevalence, and pandemic-era social distancing protocols accelerating hospital and clinic adoption of RPM platforms. The patients segment is expected to grow at the fastest rate, reflecting rising awareness of real-time health parameter monitoring and the growing availability of affordable, consumer-grade RPM devices supported by payer-assisted health plans.

Regional Outlook

North America leads the market at USD 28.8 billion in 2025, projected at USD 34.31 billion in 2026, underpinned by high adoption of monitoring devices by hospital settings and patients, strong investment in sophisticated device launches, and favorable CMS reimbursement reforms. The U.S. market alone is projected at USD 30.7 billion in 2026 — supported by the fact that 6 out of 10 U.S. adults have a chronic disease according to the CDC, generating structural demand for continuous monitoring. In March 2021, 100Plus announced a USD 25 million investment series from Henry Kravis, George Roberts, and other investors to support its RPM platform. Europe contributed USD 17.4 billion in 2025 (29.05% share), projected at USD 20.78 billion in 2026, supported by favorable regulatory frameworks, advanced healthcare infrastructure, and strategic partnerships driving comprehensive RPM solutions. The U.K. market is projected at USD 5.13 billion and Germany at USD 5.07 billion in 2026. Asia Pacific reached USD 9.93 billion in 2025 (16.58% share), projected at USD 11.89 billion in 2026, driven by growing patient awareness, company penetration in rural areas, and improving healthcare systems in India, Australia, and Southeast Asia. Japan is projected at USD 3.14 billion, China at USD 2.8 billion, and India at USD 2.21 billion in 2026. The Middle East and Africa contributed USD 1.3 billion in 2025 (2.17% share), projected at USD 1.46 billion in 2026. Latin America remains in an early-growth stage, supported by developing healthcare infrastructure and rising chronic disease prevalence.

Connect with Our Expert for any Queries: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/106328

Competitive Landscape

The global RPM devices market is fragmented, with most manufacturers emerging from developed countries competing through diversified digital platform portfolios and continuous product innovation. Key players include Koninklijke Philips N.V. (Netherlands), Medtronic (Ireland), A&D Company Limited (U.S.), Boston Scientific Corporation (U.S.), GE Healthcare (U.S.), Omron Corporation (Japan), VitalConnect (U.S.), OSPLabs (U.S.), 100Plus (U.S.), Nihon Kohden Corporation (Japan), and F. Hoffmann-La Roche AG (Switzerland). In February 2021, Philips introduced the Philips Medical Tablet enabling clinicians to remotely monitor patient health during emergencies. In August 2021, Rx. Health announced a strategic partnership with LiveCare to provide RPM systems to patients and healthcare providers. In March 2023, Monidor Oy and Senko Medical entered a partnership for remote infusion therapy monitoring services in Japan. In July 2022, Sleepiz launched a contactless respiration and heart rate measurement device for remote patient monitoring in the U.S.

What Everyone Should Know About Japan’s Market - Remote Patient Monitoring Devices Market Insights